Advertisements

Cel-Sci Corporation ($0.001 Par Value) (CVM) Stock Quote

Detailed Quote for Cel-Sci Corporation ($0.001 Par Value) (CVM)
$ 2.42   -0.03 (-1.22%) Volume: 82.37k 4:02 PM EDT Jul 20, 2017
After Hours:  $ 2.36   -0.06 (-2.48%) Volume: 1,000 4:03 PM EDT Jul 20, 2017
Today 5d 1m 3m 1y more
Last Price
2.42
Change $
0.03
Change %
1.22%
Tick
  
Bid
N/A
Bid Size
0
Ask
3.41
Ask Size
900
Open
2.35
High
2.48
Low
2.35
Prev Close
2.45
Last Trade
07/20/17
Volume
82.37k
52 Wk Hi
13.5500001
52 Wk Low
1.46000003
Market Cap
22.25m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
9,193,093
EPS (TTM)
-1.75
PE Ratio
N/A
Exchange
NYSE American
News and Media for Cel-Sci Corporation ($0.001 Par Value) (CVM)
Sector News | Topic News
News for Cel-Sci Corporation ($0.001 Par Value) (CVM)
Thu, Jul 06, 2017
7:30 AM CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016 - Business Wire
Mon, Jul 03, 2017
12:34 PM Midday Gainers / Losers - SeekingAlpha
8:00 AM Today's Research Reports on Stocks to Watch: CEL-SCI Corporation and Opko Health - ACCESSWIRE IA
Fri, Jun 30, 2017
12:43 PM Midday Gainers / Losers - SeekingAlpha
Mon, Jun 12, 2017
4:00 PM CEL-SCI Announces Reverse Stock Split - Business Wire
Thu, Jun 08, 2017
7:30 AM CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal - Business Wire
Wed, Jun 07, 2017
8:30 AM CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016 - Business Wire
Tue, Jun 06, 2017
8:03 AM CEL-SCI submits FDA response for its Phase 3 head and neck cancer trial - SeekingAlpha
Mon, Jun 05, 2017
8:00 AM CEL-SCI Submits FDA Response for Its Phase 3 Head and Neck Cancer Trial - Business Wire
Tue, May 30, 2017
1:43 PM Lifshitz & Miller LLP Announces Investigation of Akari Therapeutics, Plc, Alexion Pharmaceuticals, Inc., Amgen Inc., Cel-Sci Corp., Dick's Sporting Goods, Inc., Eco Science Solutions, Inc., Intra-Cellular Therapies, Inc. and Twilio Inc. - PR Newswire
Wed, May 24, 2017
8:08 AM FDA places CEL-SCI's late-stage Multikine study in head and neck cancer on full clinical hold; shares down 27% premarket - SeekingAlpha
7:00 AM CEL-SCI Corporation Releases Letter to Shareholders - Business Wire
Tue, May 16, 2017
8:00 AM CEL-SCI Scientist Presents at AAI - IMMUNOLOGY 2017 Meeting - Business Wire
Fri, May 12, 2017
1:00 PM CEL-SCI Announces Change to the Date of Its Annual Meeting - Business Wire
Wed, May 10, 2017
5:10 PM Cel-Sci reports Q2 results - SeekingAlpha
4:30 PM CEL-SCI Corporation Reports Second Quarter Fiscal Year 2017 Financial Results - Business Wire
Mon, May 01, 2017
8:42 AM CEL-SCI Announces $1.51 Million Registered Direct Offering - Business Wire
Fri, Apr 28, 2017
11:49 AM CEL-SCI nabs new European patent covering Multikine; shares rally 41% - SeekingAlpha
8:00 AM CEL-SCI Receives Intent to Grant Notice for New Multikine Patent from the European Patent Office - Business Wire
Mon, Apr 24, 2017
8:00 AM CEL-SCI Corporation Releases Letter to Shareholders - Business Wire
More News for CVM >>

Tags for Cel-Sci Corporation ($0.001 Par Value)

Research stocks or mutual funds related to Cel-Sci Corporation ($0.001 Par Value) by keywords or tags. Find companies that have a similar focus to CVM. The keywords below have been associated to CVM by either user submission or electronic means.

biotech research clinical trial enrollment clinical research trial clinical research software laboratory research arthritis causes corporate financial clinical cost disney annual report pharmaceutical study research institutes clinical research consulting Medical Laboratories (8071) annual report asthma clinical trial Biological Products phase iii clinical trials financial report cra clinical research research clinical research technology research phase 3 clinical trials clinical trials manager fda clinical trial medical research immunology reactive arthritis biotechnology research what causes arthritis physician clinical trials Drugs comfort research annual report of company corporate annual report 3m annual report clinical trials recruitment clinical trials conference clinical metabolic research clinical study agreements clinical data Healthcare clinical trial publication clinical research network monitoring clinical research financial statement software clinical research nurse Except Diagnostic Substances (2836) financial statement